Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
03/2005
03/10/2005US20050054717 Coumarin derivative
03/10/2005US20050054715 Vinyl phenyl derivatives as glk activators
03/10/2005US20050054713 3-Substituted oxindole beta3 agonists
03/10/2005US20050054710 Inhibits effect on various receptor tyrosine kinases and CDK (cyclin dependent kinases) complexes and on the proliferation of endothelial cells and various tumor cells
03/10/2005US20050054709 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders
03/10/2005US20050054706 N-substituted pyrroles, pyrazoles, imidazoles, triazoles and tetrazoles used for treating and preventing cancer, inflammation, autoimmune diseases, respiratory system disorders, septic shock, pain, preterm labor, as dietetics and sexual disorders, and disorders associated with MAP kinases
03/10/2005US20050054696 Indole compounds and medicinal use thereof
03/10/2005US20050054681 Coumarins as iNOS inhibitors
03/10/2005US20050054680 Agonists and antagonists of 5h3-like receptors of invertebrates as pesticides
03/10/2005US20050054679 For therapy of psychiatric and neurological disorders
03/10/2005US20050054678 Nitrogenous five-membered ring compounds
03/10/2005US20050054677 Process for preparing amine-substituted benzofurans
03/10/2005US20050054672 Quinolinone derivatives
03/10/2005US20050054668 Antagonists of MCP-1 function and methods of use thereof
03/10/2005US20050054662 Quinazoline derivatives as antitumor agents
03/10/2005US20050054656 Therapy for obesity, eating disorders, psychological disorders, antidepressants, central nervous system disorders
03/10/2005US20050054651 Compositions and methods for the treatment of disease associated with Trp-p8 expression
03/10/2005US20050054639 Viricide against human t-cell leukemia/lymphoma virus infections
03/10/2005US20050054638 Anticancer agents
03/10/2005US20050054631 Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
03/10/2005US20050054630 Fused bicyclic carboxamide derivatives and methods of their use
03/10/2005US20050054629 Antiproliferative agents; anticancer agents; restenosis
03/10/2005US20050054627 Cyclic derivatives as modulators of chemokine receptor activity
03/10/2005CA2824106A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005CA2537141A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
03/10/2005CA2537093A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005CA2536783A1 Novel chelating agents and chelates and their use
03/10/2005CA2535896A1 N-substituted benzimidazolyl c-kit inhibitors
03/10/2005CA2535265A1 Compositions and methods for the treatment of disease associated with trp-p8 expression
03/09/2005EP1512401A1 Enhancement of bone growth and inhibition of bone resorption
03/09/2005EP1512400A1 Treatment of neurodegenerative diseases
03/09/2005EP1511745A2 Protease inhibitors
03/09/2005EP1511743A1 Pyrazole-derivatives as p38 kinase inhibitors
03/09/2005EP1511734A2 Compounds, compositions, and methods
03/09/2005EP1511727A2 Aromatic sulfones and their medical use
03/09/2005EP1511491A1 Derivatives of azepine and thiazepan as interleukin converting enzyme inhibitors
03/09/2005EP1511490A2 Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
03/09/2005EP1345892B1 Acylaminoalkyl-substituted benzenesulfonamide derivatives
03/09/2005EP1307440B1 2,2-disubstituted 1,3-dioxolanes as antitussive agents
03/09/2005EP1123918B1 Aromatic amine derivatives, process for the preparation thereof and agents containing the same
03/09/2005EP1057814B1 Tetrahydrobenzindole derivatives
03/09/2005EP1018008B1 Method of identification of leads or active compounds
03/09/2005EP0991408B1 Novel process for manufacturing paroxetine solid dispersions
03/09/2005EP0869792B1 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
03/09/2005EP0817627B1 Protein kinase c inhibitors
03/09/2005CN1592746A LFA-1 antagonist compounds
03/09/2005CN1592745A Therapeutic chromone compounds
03/09/2005CN1592743A Inhibitors of glycogen synthase kinase 3
03/09/2005CN1592740A Process for the synthesis of amine ethers from secondary amino oxides and its use
03/09/2005CN1592739A Novel piperidine based MCH antagonists for treatment of obesity and CNS disorders
03/09/2005CN1592623A Acetylene derivatives having human matabotropic glutamate receptor antagonistic activity
03/09/2005CN1590386A Sidechain-bearing taxanes and method for the preparation thereof
03/09/2005CN1590378A Quinoxaline derivative and its preparation method and use
03/09/2005CN1590375A TNF-alpha prodn. inhibitors
03/09/2005CN1590374A TNF-alpha prodn. inhibitors
03/09/2005CN1192031C Epothilones derivatives, their synthesis and uses
03/09/2005CN1192027C Tricyclic fused heterocycle compounds, process for preparing the same and use thereof
03/09/2005CN1192021C 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands
03/09/2005CN1192018C Cell adhesive-inhibiting anti inflammatory and immune-suppressive compounds
03/09/2005CN1192015C Cell adhesion inhibitors
03/08/2005US6864380 Antiinflammatory agents; asthma; antiallergens; autoimmune diseases; antiarthritic agents
03/08/2005US6864368 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
03/08/2005US6864284 Ascorbic acid compounds, methods of synthesis and application use thereof
03/08/2005US6864277 Brain diosrders; cardiovascular disorders; central nervous system disorders; psychological disorders
03/08/2005US6864273 Dyspepsia; gastrointestinal disorders; irritable bowel disorders
03/08/2005US6864266 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
03/08/2005US6864265 Chemokine receptor binding heterocyclic compounds
03/08/2005US6864263 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
03/08/2005US6864261 Substituted piperzino-pyridine compound, useful for treting pain, anxiety, urinary incontinence, an addictive disorder, Parkinson's disease, epilepsy, psychosis, and used as Selective antagonists of the metabotropic glutamate receptor 5
03/08/2005US6864252 Treatment of cyclooxygenase mediated diseases, such as arthritis, neurodegeneration and colon cancer
03/08/2005CA2261680C Fluorine-containing 1,4-disubstituted piperidine derivatives
03/03/2005WO2005019216A1 Aminobenzimidazole derivatives
03/03/2005WO2005019209A2 Crystalline anhydrous paroxetine hydrochloride
03/03/2005WO2005019201A2 Process for the preparation of 4-amino-3-quinolinecarbonitriles
03/03/2005WO2005019200A2 Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
03/03/2005WO2005019196A1 3-aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
03/03/2005WO2005019182A1 Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists
03/03/2005WO2005019181A1 Migrastatin analog cell migration inhibitors
03/03/2005WO2005019177A1 Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
03/03/2005WO2005019174A1 Acetylene derivatives as inhibitors of histone deacetylase
03/03/2005WO2005019172A1 Indol-2-amides as glycogen phosphorylase inhibitors
03/03/2005WO2005019168A2 Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
03/03/2005WO2005018557A2 Substituted pyridinones
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005US20050049413 Quinoline derivatives
03/03/2005US20050049292 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression
03/03/2005US20050049290 Benzimidazole derivatives and their use as gnrh antagonists
03/03/2005US20050049288 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS
03/03/2005US20050049283 Compounds that inhibit factor xa activity
03/03/2005US20050049280 e.g., ethyl 4-(hydroxyaminocarbonyl)-4-[4-(p-trifluoromethylphenoxy)piperidin-1-ylsulfonyl]piperidine-N-carboxylate
03/03/2005US20050049267 Pin1-modulating compounds and methods of use thereof
03/03/2005US20050049264 Suppressing growth of abnormal cells; gastric, brain, colon, pancreatic, lung, renal, ovarian and prostatic cancer
03/03/2005US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease
03/03/2005US20050049257 e.g., 5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine; used in treating anxiety disorders, depression and stress related disorders
03/03/2005US20050049252 Treating arthritis, pain and cancer; cyclooxygenase-2 inhibitors
03/03/2005US20050049247 Pyrimidines useful as modulators of voltage-gated ion channels
03/03/2005US20050049237 Pyrazole-amides and -sulfonamides
03/03/2005US20050048315 Such as 4-(dicyanomethylene)-2-{p-(dialkylamino)styryl}-6-{p-(diarylamino)styryl}-4H-pyran; improved carrier transportation and exhibits long wavelength light
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
1 ... 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 ... 694